Search

Your search keyword '"Romano, F. J."' showing total 20 results
Start Over Author "Romano, F. J."
20 results on '"Romano, F. J."'

1. Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results

Author

Lococo, Filippo, Cancellieri, Alessandra, Chiappetta, M., Leonetti, A., Cardillo, G., Zanelli, F., Mangiameli, G., Toschi, L., Guggino, G., Romano, F. J., Leuzzi, G., Proto, C., Spaggiari, L., De Marinis, F., Vita, Emanuele, Ampollini, L., Margaritora, Stefano, Tiseo, M., Bria, Emilio, Lococo,F. (ORCID:0000-0002-9383-5554), Cancellieri,A., Vita, E., Margaritora, S. (ORCID:0000-0002-9796-760X), Bria, E. (ORCID:0000-0002-2333-704X), Lococo, Filippo, Cancellieri, Alessandra, Chiappetta, M., Leonetti, A., Cardillo, G., Zanelli, F., Mangiameli, G., Toschi, L., Guggino, G., Romano, F. J., Leuzzi, G., Proto, C., Spaggiari, L., De Marinis, F., Vita, Emanuele, Ampollini, L., Margaritora, Stefano, Tiseo, M., Bria, Emilio, Lococo,F. (ORCID:0000-0002-9383-5554), Cancellieri,A., Vita, E., Margaritora, S. (ORCID:0000-0002-9796-760X), and Bria, E. (ORCID:0000-0002-2333-704X)

Abstract

Background: The role of salvage surgery after tyrosine kinase inhibitors in advanced oncogene-addicted non-small cell lung cancer is largely unexplored. Patients: We aimed to describe the pathological features and surgical early-outcomes of Anaplastic Lymphome Kinase anaplastic lymphome kinase positive non-small cell lung cancer patients undergoing surgery after first-line alectinib treatment. We retrospectively collected and analyzed multicentric data of 10 patients treated with alectinib for advanced-stage anaplastic lymphome kinase positive lung adenocarcinoma who underwent anatomical surgical resection from January 2020 to Decemeber 2021. All patients were treatment naive and received alectinib (600 mg twice daily). Surgery was always proposed after multidisciplinary discussion. The primary endpoints were pathological response and surgical feasibility (technical intraoperative complications, postoperative outcomes). Results: Alectinib was received for a mean of 212 days before surgery (42-415 days) and was generally interrupted about one week before surgery (range: 0-32 days) with no patient experienced grade 4 toxicity. All patients received an R0 resection with surgery consisting of lobectomy in 8 cases with bilobectomy and (left) pneumonectomy in 1 case each. Intra-operative difficulties were described in 7 cases (70%), mostly due to perivascular fibrosis or thickening of mediastinal lymph nodal tissues. Major and minor complications occurred in 0 and 3 cases (30%), respectively. A pathological complete response and major pathological response (defined as 0% and < 10% viable tumor cells, respectively) were observed in 50% and 90% of cases, respectively. Despite short follow-up, only one tumor recurrence was observed (in the only patient who did not resume alectinib after surgery). Interpretation: Despite some technical intraoperative difficulties, salvage surgery was safe and feasible after Alectinib for advanced lung adenocarcinoma.

Published
2023

2. Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: Biochemical and pathophysiological evidences [Oncotarget, 8, (2017) (30606-30616)] doi 10.18632/oncotarget.16725

Author

Quagliariello, V., Rossetti, S., Cavaliere, C., Di Palo, R., Lamantia, E., Castaldo, L., Nocerino, F., Ametrano, G., Cappuccio, F., Malzone, G., Montanari, M., Vanacore, D., Romano, F. J., Piscitelli, R., Iovane, G., Pepe, M. F., Berretta, M., D'Aniello, C., Perdona, S., Muto, P., Botti, G., Ciliberto, G., Veneziani, B. M., De Falco, F., Maiolino, P., Caraglia, M., Montella, M., Iaffaioli, R. V., and Facchini, G.

Subjects
endocrine disruptors, nutrition, prostate, cancer, metabolic syndrome
Published
2017

8. Sarcomatoid larynx carcinoma differential clinical evolution, on field statistical considerations

Author

Marco Bocchetti, Massimo Mesolella, Flavia Oliva, Raul Pellini, Bruno Chiurazzi, Francesco Jacopo Romano, Remo Palladino, Raffaele Addeo, Michele Caraglia, Amedeo Boscaino, Salvatore Mazzone, Gerardo Petruzzi, Filippo Ricciardiello, Brigida Iorio, Ricciardiello, F., Bocchetti, M., Pellini, R., Palladino, R., Caraglia, M., Boscaino, A., Petruzzi, G., Romano, F. J., Chiurazzi, B., Addeo, R., Mazzone, S., Mesolella, M., Oliva, F., and Iorio, B.

Subjects
Adult, Male, Larynx, Oncology, medicine.medical_specialty, Survival, Cell, Statistical analysi, Antineoplastic Agents, Spidle cell carcinoma, Antineoplastic Agent, 03 medical and health sciences, 0302 clinical medicine, Cancer stem cell, Squamous cell carcinoma, Internal medicine, medicine, Humans, In patient, Epithelial–mesenchymal transition, 030223 otorhinolaryngology, Laryngeal Neoplasms, Aged, Neoplasm Staging, Aged, 80 and over, Laryngeal Neoplasm, business.industry, Cancer, Sarcoma, Middle Aged, medicine.disease, Survival Rate, medicine.anatomical_structure, Larynx carcinoma, Otorhinolaryngology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Cohort, Carcinoma, Squamous Cell, Female, Neoplasm Recurrence, Local, business, Human
Abstract

Spindle cell larynx carcinoma (SpCC) represents around 3% of laryngeal cancers. It is originated by a single cancer stem cell undergoing epithelial to mesenchymal transition. This explains the aggressiveness, the peculiar resistance to conventional therapy and the frequent relapses. We focused on this particular cancer subset characteristics in patients, in early and advanced stages primarily aiming to define and highlight the differences with Laryngeal Squamous Cell Carcinoma (LSCC) focusing on clinical features, treatments, follow-up and survival in a patient's cohort composed by comparable cases from two subgroups.

Published
2021
Full Text
View/download PDF

9. Rectal/urinary toxicity after hypofractionated vs. conventional radiotherapy in high risk prostate cancer: systematic review and meta analysis.

Author

Di Franco R, Borzillo V, Ravo V, Ametrano G, Cammarota F, Rossetti S, Romano FJ, D'Aniello C, Cavaliere C, Iovane G, Porricelli MA, Muto M, Berretta M, Facchini G, and Muto P

Subjects
Dose Fractionation, Radiation, Gastrointestinal Diseases etiology, Humans, Male, Radiotherapy, Intensity-Modulated, Randomized Controlled Trials as Topic, Rectum pathology, Prostatic Neoplasms radiotherapy, Radiation Injuries etiology
Abstract

Objective: The aim of our report was to review the literature concerning the toxicity of radiation therapy in patients treated for high-risk prostate cancer, and to evaluate the differences in toxicity between conventional fractionation and hypofractionated treatments, in view of different techniques used in high-risk prostate cancer patients., Materials and Methods: PubMed database has been explored for studies concerning acute and late urinary/gastrointestinal toxicity in high-risk prostate cancer patients treated with radiotherapy. Prospective studies, concerning potential relationship between acute/late genitourinary (GU)/gastrointestinal (GI) toxicity and prostate radiotherapy in patients with high-risk prostate cancer, were included in the final analysis. Data collected from single arm, phase II non-randomized and randomized studies have been evaluated to perform odds ratio for toxicity risk. Furthermore, meta-analysis randomized prospective trials were considered suitable because they had recruited high-risk prostate cancer patients who didn't undergo surgery, with available data on ≥ G2 toxicity frequency., Results: The initial search provided 606 results, but only 35 manuscripts met all eligibility requirements and were included in this report. In order to perform odds ratio we observed a decrease in late gastrointestinal toxicity for patients treated with hypofractionated schemes compared to CV treated ones. Among patients who underwent conventional treatment, SIB seemed to decrease acute genitourinary side effects; SIB-Hypo treated patients suffered less toxicity than patients treated with hypofractionated- sequential boost schemes. Hypo-SIB schemes would seem less toxic in terms of acute gastrointestinal and late genitourinary side effects than CV-SIB. Therefore, our focus shifted to 6 clinical trials evaluating genitourinary and gastrointestinal toxicity in patients who had been randomized to receive conventional fractionation or hypofractionated treatment, in both cases with IMRT technology. Our meta-analysis of these randomized trials involving patients with high-risk prostate cancer showed a statistically significant increase in late genitourinary toxicity for hypo-treated patients; no difference was observed in acute genitourinary/gastrointestinal toxicity, and in late gastrointestinal toxicity., Conclusions: Our analysis doesn't want to establish a definitive truth; very few trials assessed only high risk-class patients. Our purpose is to stimulate further randomized prospective trials focusing both on the effectiveness and toxicity profile (toxicity/effectiveness ratio), taking into account the use of different technologies and doses.

Published
2017

13. [Exercise test using a telemetric recording].

Author

Menna J, Traina M, Cristiano E, and Romano FJ

Subjects
Adult, Aged, Female, Humans, Male, Methods, Middle Aged, Electrocardiography, Exercise Test, Myocardial Infarction diagnosis, Telemetry
Published
1971

Catalog

Books, media, physical & digital resources
See catalog results